During foodborne illness outbreak investigations, comparing food exposure frequencies of cases to those of a control population can help identify suspect food sources. The Public Health Agency of Canada (PHAC) conducted an online survey between February and April 2015 to collect seven-day food exposures from a convenience sample. The study period overlapped with a national, population-based exposure survey being conducted via telephone using random digit dialling. https://www.selleckchem.com/products/jph203.html A subset of the food exposure questions from the telephone-based survey was included in the online survey. The online survey study objectives were to 1) describe the survey methodology, survey respondents and response behaviour; and 2) determine if the online methodology is an appropriate alternative to telephone surveys by comparing food exposures. The online survey link was distributed via email to employees and public health partners, and was promoted on the PHAC website and social media channels. In total 2,100 surveys were completed. The majority of respondents were female, with high income and education, aged 30 to 39 years. The proportion reporting consuming the food items in the online survey was generally higher than those reported in the telephone survey, with a mean difference of 6.0% (95% CI 4.2, 7.8). In an outbreak investigation, the 6.0% bias could make it more difficult to detect a difference between the case and control food exposures. Nevertheless, given the speed of response and lower resource expenditure of online surveys as well as the willing, able and convenient sample, a bias of 6.0% is considered small enough to be acceptable for future surveys. In an outbreak investigation, the 6.0% bias could make it more difficult to detect a difference between the case and control food exposures. Nevertheless, given the speed of response and lower resource expenditure of online surveys as well as the willing, able and convenient sample, a bias of 6.0% is considered small enough to be acceptable for future surveys.Canada's national influenza season typically starts in the latter half of November (week 47) and is defined as the week when at least 5% of influenza tests are positive and a minimum of 15 positive tests are observed. As of December 12, 2020 (week 50), the 2020-2021 influenza season had not begun. Only 47 laboratory-confirmed influenza detections were reported from August 23 to December 12, 2020; an unprecedentedly low number, despite higher than usual levels of influenza testing. Of this small number of detections, 64% were influenza A and 36% were influenza B. Influenza activity in Canada was at historically low levels compared with the previous five seasons. Provinces and territories reported no influenza-associated adult hospitalizations. Fewer than five hospitalizations were reported by the paediatric sentinel hospitalization network. With little influenza circulating, the National Microbiology Laboratory had not yet received samples of influenza viruses collected during the 2020-2021 season for strain characterization or antiviral resistance testing. The assessment of influenza vaccine effectiveness, typically available in mid-March, is expected to be similarly limited if low seasonal influenza circulation persists. Nevertheless, Canada's influenza surveillance system remains robust and has pivoted its syndromic, virologic and severe outcomes system components to support coronavirus disease 2019 (COVID-19) surveillance. Despite the COVID-19 pandemic, the threat of influenza epidemics and pandemics persists. It is imperative 1) to maintain surveillance of influenza, 2) to remain alert to unusual or unexpected events and 3) to be prepared to mitigate influenza epidemics when they resurge. Filamin A is an actin-crosslinking protein expressed in many malignancies, although its prognostic and therapeutic role in breast cancer is not studied. There is enigma regarding its dual role in cancer, the tumor-progressing or tumor-suppressing effects depending on the site to which it localizes in the cell. The current study aimed to detect Filamin A expression in breast cancer and its association with other biomarkers and other clinicopathological parameters and established risk factors in breast cancer so that it can be a potential site for targeted therapy. One hundred female patients of histologically proven breast cancer who presented to our hospital over a 2-year period were included in the study. None of the patients received prior radiotherapy, chemotherapy, or immunotherapy. Patients with recurrent breast cancer are not included in the study. All study cases are subjected to immunohistochemistry for estrogen receptor, progesterone receptor, Her2 neu, and ki-67 from core biopsy tissue of cases A expression and clinicopathological parameters in our study. The cytoplasmic expression is seen in malignant cells as well as normal breast and benign tumor sections implicating the dual role of Filamin A in breast cancer. Filamin A immunoexpression should be further correlated with metastasis-free survival period of breast cancer patients. No significant correlation could be found between Filamin A expression and clinicopathological parameters in our study. The cytoplasmic expression is seen in malignant cells as well as normal breast and benign tumor sections implicating the dual role of Filamin A in breast cancer. Filamin A immunoexpression should be further correlated with metastasis-free survival period of breast cancer patients. Spalt-like transcription factor 4 (SALL4) is a stem cell marker that plays a critical role in maintaining the pluripotency and self-renewal of embryonic and hematopoietic stem cells. Only a few studies have been done to apprehend the expression of SALL4 in the potentially malignant oral lesion (leukoplakia with dysplasia) and oral squamous cell carcinoma (OSCC). The aim of this study is to evaluate the expression of SALL4 in leukoplakia with dysplasia and OSCC and to correlate the expression of the marker (SALL4) with the various clinicopathological parameters and patient outcome. Immunohistochemistry for SALL4 protein was performed on 140 cases those histopathologically confirmed cases of leukoplakia with dysplasia ( = 30) and OSCC ( = 110). Ten cases of nonepithelial neoplasm (fibroepithelial hyperplasia and excised tissue surrounding impacted third molars) were taken as control. Statistical analyses were applied to evaluate correlations between SALL4 overexpression and clinicopathological features of leukoplakia and OSCC.